|Chemotherapy Agents||Incidence (%)||Frequency of Use|
|Histone deacetylase inhibitor|
|Vorinostat (Zolinza) (10,131)||3.5–6||+|
|Arsenic trioxide (Trisenox) (10,163–170)||26–93⁎||+|
|Small molecule tyrosine kinase inhibitors|
|Dasatinib (Sprycel) (10)||<1–3||++|
|Lapatinib (Tykerb) (10)||16||+|
|Nilotinib (Tasigna) (171–173)||1–10||+|
For an explanation of the + symbols, please see Table 1.
↵⁎ The incidence of QT prolongation varies widely in the literature for arsenic due to the differences in study design, definition of QT prolongation, and numbers of patients. Medication manufacturers and locations: Trisenox, Cephalon Oncology, Frazer, Pennsylvania; Tasigna, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; others as in Tables 1 and 4.